TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01738152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLA vaginal gel (HyaloGYN®),
Description: Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
Study: NCT02660736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide Liquid Auto-injector
Description: Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide Liquid Auto-injector
Description: Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide Lyophilized DCC Pen Injector
Description: Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide Lyophilized DCC Pen Injector
Description: Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Liquid Auto-injector
Description: Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Liquid Auto-injector
Description: Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Lyophilized DCC Pen injector
Description: Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Lyophilized DCC Pen injector
Description: Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
Study: NCT01297842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem 1 gram per day for 7 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem or Imipenem
Description: Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
Study: NCT02950636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Restorative Yoga
Study: NCT02437929

Intervention type: PROCEDURE
Intervention: Mobilization

Intervention type: PROCEDURE
Intervention: Positioning

Intervention type: PROCEDURE
Intervention: Personal Hygiene Care

Intervention type: PROCEDURE
Intervention: Bladder catheterization

Intervention type: PROCEDURE
Intervention: Wound care

Intervention type: PROCEDURE
Intervention: Subcutaneous drugs administration
Study: NCT04206436

Intervention type: DRUG
Intervention: Cftr Modulators
Description: CFTR modulators are drugs used to treat cystic fibrosis
Study: NCT01551329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketalar (ketamine)
Description: Intravenous Ketamine 0.5mg/kg
Study: NCT01540227

Intervention type: DRUG
Intervention: Regular Treatment for Syphilis
Description: Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes
Study: NCT02242331

Intervention type: DRUG
Intervention: Micardis®
Study: NCT04317586

Intervention type: DEVICE
Group type: OTHER
Intervention: Trident II Tritanium Acetabular Shell for Revision
Description: A hemispherical acetabular shell indicated for cementless application in a previously failed total hip arthroplasty (THA)
Study: NCT04337567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: ablative treatment as allocated to radiofrequency ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ballon cryoablation
Description: ablative treatment as allocated to ballon cryoablation
Study: NCT00136708

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Neonatal Resuscitation
Study: NCT00242567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
Study: NCT01038531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-tidal-volume ventilation
Description: goal tidal volume of 6 cc/kg ideal body weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRV
Description: APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
Study: NCT01735864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirubin 200μg/g
Description: 1. Dosage form: Ointment~2. Dose(s): Each gram of ointment containing 200 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
Study: NCT00136708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neonatal Resuscitation
Study: NCT02717533

Intervention type: OTHER
Intervention: dry weight adjustment
Description: dry weight change to match ideal blood volume obtained by blood volume measurement.
Study: NCT02509741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food replacement
Study: NCT01735864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirubin 100 μg/g
Description: 1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 100 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirubin 50 μg/g
Description: 1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 50 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirubin 10 μg/g
Description: 1. Dosage form: Ointment~2. Dose(s): Each gram of ointment contains 10 μg of indirubin~3. Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily
Study: NCT06440044

Intervention type: OTHER
Intervention: Data collection
Description: A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.

Intervention type: OTHER
Intervention: Data collection
Description: A prospectively maintained database query of all patients with CRC and VTE was initially performed, and then each patient's electronic record was reviewed for inclusion criteria.
Study: NCT06542172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500 mL/day of full-fat milk from corn-fed cows (fat >3.8%) for 12 weeks
Description: All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500 mL/day of full-fat milk from grass-fed cows (fat >3.8%) for 12 weeks
Description: All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 500 mL/day of low-fat milk (fat <1.5%) for 12 weeks
Description: All milk is provided by the Inner Mongolia Yili Industrial Group Limited by Share Ltd (Inner Mongolia, China).
Study: NCT04382560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing training
Description: The intervention will comprise a psychoeducational part on the theorethical background underlying this technique and a pratical session in which partecipant will be instructed to inhale air with his/her nose and exhale with his/her mouth for a period of 3 seconds of inhalation and 7 seconds of exhalation (i.e., 6 cycles of breaths per minute;). During the session, the participant will be encouraged to put one hand over his/her chest and the other over the abdomen in order to see the difference between normal breathing and deep breathing. To help the subjects in the training, an online pacer will give the rhythm of respiration and will be used as visual feedback.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion focused intervention
Description: The short compassion focused intervention will begin with a short psychoeducation on the evolved nature and difficulties of the human mind, such as tendencies for negativity bias, negative rumination, and self-criticism. Participants will then be offered insights into how humans can work with their 'tricky brains' using body-based and psychological-based practices aimed at increasing a grounding and soothing compassionate attitude towards ourselves and others. In particular, participants will be instructed to pratice a mindfulness technique designed to help them to become more aware of their present moment-to-moment and more compassionate towards their own emotions. They will then be guided to create an image conveying warmth and compassion to them. Lastly, participants will be guided to bring the image to mind and then write write a brief self-compassionate letter to themselves from that point of view.
Study: NCT01070407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut; AdCh3NSmut
Description: 2 doses Ad6NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut; AdCh3NSmut
Description: 2 doses Ad6NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut; AdCh3NSmut
Description: 2 doses Ad6NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut; Ad6NSmut
Description: 2 doses AdCh3NSmut 5 x 10\^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut; Ad6NSmut
Description: 2 doses AdCh3NSmut 5 x 10\^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut; Ad6NSmut
Description: 2 doses AdCh3NSmut 2.5 x 10\^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad6NSmut; AdCh3NSmut
Description: 1 dose Ad6NSmut 2.5 x 10\^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut; Ad6NSmut
Description: 1 dose AdCh3NSmut 2.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10\^10vp at week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut; Ad6NSmut
Description: 1 dose AdCh3NSmut 7.5 x 10\^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10\^10vp at week 8.
Study: NCT01977560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Participants will be instructed to consume \~500 kcal/day less than their calculated estimated total daily energy requirements. The supervised exercise program will include both endurance and resistance exercise training sessions. The doses of diabetes medications will be adjusted by study physicians every 1-2 weeks, as needed to avoid hypoglycemia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: After receiving dietary and physical activity instructions as recommended by the American Diabetes Association (ADA) guidelines participants will meet approximately every month for about 7 months with a study team member to record body weight, review diet and physical activity behaviors, and document medication use. Participants will continue their routine medical management, including regular clinic visits with their personal physician and/or diabetes educator during their participation in this study. Any changes medications will made by the participants' personal physician(s).
Study: NCT04332835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard therapy defined by institutional protocol.
Study: NCT02509741

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food replacement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IOT monitoring
Study: NCT04332835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Therapy
Description: Standard therapy defined by institutional protocol.
Study: NCT02218515

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Flap Debridement
Description: Open Flap Debridement (Control Group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EmdogainⓇ(Enamel Matrix Derivative)
Description: Open Flap Debridement+Enamel Matrix Derivative

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EmdogainⓇEnamel Matrix Derivative+Autogenous Bone
Description: Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
Study: NCT01224418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study: NCT05549986

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT02875119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Griffithsin Gel
Description: Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel
Study: NCT02428491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hexaxim®
Description: DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
Study: NCT02066688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
Study: NCT01235910

Intervention type: DRUG
Group type: OTHER
Intervention: Aliskiren
Description: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Study: NCT01586442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
Study: NCT02066688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid calcium vitamin D3
Description: Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium
Description: calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
Study: NCT01861717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide
Description: Somatuline Depot 90 mg deep subcutaneous injection every 4 weeks X 3 doses
Study: NCT01413685

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Pharmacokinetics/dynamics
Description: Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
Study: NCT00910065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV
Description: Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV
Description: Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Description: Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
Study: NCT03586869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin Hydrochloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study: NCT00557830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Escalated Dose
Description: Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib Standard Dose
Description: Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
Study: NCT03165630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation incentives
Description: Free transportation only for the first 3 months post-discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transportation and rehabilitation services incentives
Description: Free transportation and rehabilitation services 3 months post-discharge.
Study: NCT02395094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Life
Description: Child Life preparation in surgical daycare can include:~* role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~* the use of books/storyboards that show pictures of operating room and daycare routines~* teaching \& rehearsing coping and relaxation skills such as deep breathing and guided imagery~* age-appropriate explanation of what to expect throughout the day in SDCU